Jennifer Griffin
Investor at Mission BioCapital
United States
Overview
Work Experience
Partner, Strategy & Investor Relations
2021 - Current
Mission BioCapital is a life science venture capital firm that invests in early-stage companies.
Raised $11,000,001.00.
Board Observer
2021 - 2021
EnVision Endoscopy is a medical device that provides endoscopic surgeries with solutions.
Raised $3,368,452.00 from MassVentures, MassVentures, MassVentures, National Science Foundation, National Science Foundation, MassChallenge, Massachusetts Life Sciences Center and National Science Foundation.
Board Observer
2020 - 2021
Nutrimedy defining telenutrition through novel online platform based on the integration of leading edge science, technology & health.
Raised $3,030,000.00 from Massachusetts Life Sciences Center.
VP, Industry Strategy & Investments
2017 - 2021
The Massachusetts Life Sciences Center (MLSC) is a quasi-state agency that supports life sciences innovation, education, research & development, and commercialization. The MLSC is charged with deploying a $1.6 billion, state-funded investment initiative. Responsible for developing and executing the Commonwealth's overall investment strategy with a focus on supporting early stage companies, recruiting and retaining companies of all stages and talent, and diversifying our industry. Created and managed the $2M Seed Fund, $2M+ public-private partnership MassNextGen to support women entrepreneurs, and other investment programs for early-stage companies. Developed and managed the strategy and execution of the business development efforts that recruit and retain life science companies in the Commonwealth of Massachusetts. Oversaw $40M+ annually in the newly overhauled Capital Programs in order to drive industry partnerships with academia that target specific industry gaps. Developed $10M+ in new Women's Health-focused investment to drive innovation and industry partnership in the space.
The Massachusetts Life Sciences Center (MLSC) aims to create jobs in the life sciences and support vital scientific research.
Raised $6,220,000.00.
Board Obserer
2018 - 2021
Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
Raised $86,868,856.00 from Mission BioCapital, Engine Ventures, RA Capital Management, Global Health Investment Corporation, The Engine, Global Health Investment Corporation, RA Capital Management and Ulu Ventures.
Senior Consultant
2016 - 2017
Consultant
2015 - 2016
Advised companies from venture-backed to large pharma and med device on broad commercial topics including product positioning and commercial opportunity, exit strategies, business unit and corporate growth strategies, R&D prioritization, life-cycle management, and asset and company diligence.
Back Bay Life Science Advisors provides strategy consulting and transaction advisory services to the life science industry.
Raised $1,551,796.00.
Associate Licensing Officer
2013 - 2014
Managed all aspects of commercializing MIT life science technologies including technology assessment, patent prosecution, sourcing opportunities, license structuring and negotiation, license compliance and alliance management.
Technology Licensing Associate
2011 - 2013
Supported all efforts of licensing and commercializing MIT life science technologies.
Licensing Intern, Office of Technology Management
2010 - 2011
Evaluation of early stage life science technologies including patentability and commercial viability. Developed succinct, accurate and persuasive targeted marketing material for early stage life science technologies with a focus on RNAi therapeutics and delivery technologies.
Ph.D. Candidate
2005 - 2011
Dept. of Molecular Genetics and Microbiology Lab of Dr. Christopher Sassetti Howard Hughes Medical Investigator Investigated the role of cholesterol in Mycobacterium tuberculosis pathogenesis using transposon mutagenesis and next generation sequencing technology.